Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
ReutersWed, May 13, 2026 at 8:51 PM UTC
0
Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon
May 13 (Reuters) - Japan's Takeda Pharmaceutical plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
The company expects annual savings of more than 200 billion yen ($1.27 billion) by fiscal 2028, with about 100 billion yen expected in fiscal 2026, it said in its fourth-quarter earnings presentation on Wednesday, without providing further details about the timeline and which roles will be affected.
Takeda did not immediately respond to a Reuters request for comment.
The company has been in the midst of a years-long overhaul following its $62 billion acquisition of Shire in 2019, which expanded its global footprint but added debt and complexity.
It said in the presentation that it anticipates restructuring costs of around 170 billion yen in fiscal 2026, with lower amount expected in the next two years.
Advertisement
Takeda's announcement comes after Danish drugmaker Novo Nordisk said in September it would slash 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs.
Earlier this month, Takeda's experimental treatment for primary immunodeficiency disease met the main goal in a mid-to late-stage study, with the company planning to seek approvals in the U.S., the European Union and Japan in 2026.
Takeda reported revenue of 4.51 trillion yen during fiscal 2025, down 1.7% from a year earlier.
($1 = 157.8300 yen)
(Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)
Source: “AOL Money”
